elliptinium has been researched along with acriflavine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanquet, D; Hallard, M; Mathé, G; Morette, C; Pontiggia, P; Triana, K | 1 |
| Mathé, G | 1 |
| Blanquet, D; Hage, F; Hallard, M; Mathe, G; Morette, C; Pontiggia, P | 1 |
2 review(s) available for elliptinium and acriflavine
| Article | Year |
|---|---|
Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostatics.
Topics: Acriflavine; Anti-HIV Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Ellipticines; HIV Infections; Humans; Treatment Outcome; Zidovudine | 1998 |
Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment? A ten-year experience [correction of experiment] must liberate them.
Topics: Acquired Immunodeficiency Syndrome; Acriflavine; Cobalt; Ellipticines; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Vitamin B 12 | 1999 |
1 other study(ies) available for elliptinium and acriflavine
| Article | Year |
|---|---|
Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation.
Topics: Acquired Immunodeficiency Syndrome; Acriflavine; Adult; Anti-HIV Agents; Antiviral Agents; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Ellipticines; Female; Follow-Up Studies; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Stavudine; Vitamin B 12; Zalcitabine; Zidovudine | 2002 |